Janus Henderson Group PLC Has $40.29 Million Holdings in Cytokinetics, Inc. (CYTK)

Janus Henderson Group PLC increased its position in shares of Cytokinetics, Inc. (NASDAQ:CYTK) by 3.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,778,605 shares of the biopharmaceutical company’s stock after acquiring an additional 93,675 shares during the period. Janus Henderson Group PLC owned about 5.16% of Cytokinetics worth $40,290,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Vanguard Group Inc. boosted its position in shares of Cytokinetics by 59.9% during the 2nd quarter. Vanguard Group Inc. now owns 3,117,496 shares of the biopharmaceutical company’s stock worth $37,721,000 after acquiring an additional 1,168,151 shares in the last quarter. State Street Corp boosted its position in shares of Cytokinetics by 79.6% during the 2nd quarter. State Street Corp now owns 1,674,335 shares of the biopharmaceutical company’s stock worth $20,259,000 after acquiring an additional 741,909 shares in the last quarter. Pinnacle Associates Ltd. acquired a new stake in shares of Cytokinetics during the 3rd quarter worth approximately $14,628,000. Citigroup Inc. boosted its position in shares of Cytokinetics by 9.9% during the 2nd quarter. Citigroup Inc. now owns 800,471 shares of the biopharmaceutical company’s stock worth $9,686,000 after acquiring an additional 71,811 shares in the last quarter. Finally, Balyasny Asset Management LLC boosted its position in shares of Cytokinetics by 24.5% during the 2nd quarter. Balyasny Asset Management LLC now owns 631,800 shares of the biopharmaceutical company’s stock worth $7,645,000 after acquiring an additional 124,300 shares in the last quarter. Institutional investors and hedge funds own 73.61% of the company’s stock.

In other news, EVP Fady Ibraham Malik sold 7,321 shares of the firm’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $13.39, for a total transaction of $98,028.19. Following the completion of the transaction, the executive vice president now owns 47,540 shares of the company’s stock, valued at $636,560.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Caryn Gordon Mcdowell sold 4,260 shares of the firm’s stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $12.94, for a total transaction of $55,124.40. Following the transaction, the insider now directly owns 17,982 shares of the company’s stock, valued at approximately $232,687.08. The disclosure for this sale can be found here. Insiders have sold 34,762 shares of company stock valued at $497,826 in the last ninety days. Insiders own 7.20% of the company’s stock.

Several analysts recently issued reports on the stock. Needham & Company LLC downgraded shares of Cytokinetics from a “strong-buy” rating to a “buy” rating and dropped their price objective for the company from $22.00 to $12.00 in a research note on Wednesday, November 29th. Morgan Stanley reissued an “overweight” rating and issued a $17.00 price objective (down previously from $25.00) on shares of Cytokinetics in a research note on Wednesday, November 22nd. Cantor Fitzgerald downgraded shares of Cytokinetics from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $21.00 to $10.00 in a research note on Wednesday, November 22nd. ValuEngine downgraded shares of Cytokinetics from a “hold” rating to a “sell” rating in a research note on Tuesday, November 21st. Finally, JMP Securities reissued an “outperform” rating and issued a $13.00 price objective (down previously from $17.00) on shares of Cytokinetics in a research note on Tuesday, November 21st. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the stock. Cytokinetics presently has a consensus rating of “Buy” and a consensus price target of $17.64.

Cytokinetics, Inc. (NASDAQ:CYTK) opened at $8.15 on Wednesday. Cytokinetics, Inc. has a 52 week low of $7.00 and a 52 week high of $17.20. The company has a debt-to-equity ratio of 0.14, a quick ratio of 7.60 and a current ratio of 7.60.

Cytokinetics (NASDAQ:CYTK) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.64) by $0.04. The firm had revenue of $6.18 million during the quarter, compared to the consensus estimate of $5.35 million. Cytokinetics had a negative net margin of 172.27% and a negative return on equity of 62.64%. research analysts expect that Cytokinetics, Inc. will post -2.4 earnings per share for the current fiscal year.

WARNING: “Janus Henderson Group PLC Has $40.29 Million Holdings in Cytokinetics, Inc. (CYTK)” was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://www.com-unik.info/2017/12/20/janus-henderson-group-plc-has-40-29-million-holdings-in-cytokinetics-inc-cytk.html.

About Cytokinetics

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.

Institutional Ownership by Quarter for Cytokinetics (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit